Please wait while the formulary information is being retrieved.
VYXEOS (DAUNORUBICIN/CYTARABINE LIPOSOMAL)
- Acute myeloid leukemia
44 mg-100 mg intravenous solution
- Dosage information is not available
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- ado-trastuzumab emtansine
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Herceptin
- Kadcyla
- trastuzumab
- Versacloz
Severe
Moderate
- Digox
- digoxin
- Lanoxin
- Lactating mother
Contraindicated
- Cardiomyopathy
- Chronic heart failure
- Heart block
- Increased risk of bleeding
- Pregnancy
Severe
Moderate
- Wilson's disease
VYXEOS (DAUNORUBICIN/CYTARABINE LIPOSOMAL)
- Acute myeloid leukemia
- Cardiac arrhythmia
- Dyspnea
- Pneumonia
- Acute abdominal pain
- Anorexia
- Bacteremia
- Chills
- Constipation
- Cough
- Diarrhea
- Edema
- Epistaxis
- Fatigue
- Fever
- Headache disorder
- Musculoskeletal pain
- Nausea
- Skin rash
- Sleep disorder
- Stomatitis
- Vomiting
More Frequent
Severe
Less Severe
- Bacterial sepsis
- Cardiomegaly
- Cardiomyopathy
- Cardiotoxicity
- Fungal infection
- Hearing loss
- Hypersensitivity drug reaction
- Hypertension
- Hypotension
- Hypoxia
- Interstitial pneumonitis
- Intracerebral hemorrhage
- Kidney disease with reduction in GFR
- Neutropenic disorder
- Pleural effusions
- Thrombocytopenic disorder
- Angina
- Chest pain
- Conjunctival hyperemia
- Conjunctivitis
- Delirium
- Dizziness
- Dry eye
- Dyspepsia
- Eyelid edema
- Hallucinations
- Hemorrhoids
- Injection site sequelae
- Ocular discomfort
- Ocular irritation
- Ocular pain
- Periorbital edema
- Pruritus of skin
- Symptoms of anxiety
- Upper respiratory infection
- Visual changes
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute coronary syndrome
- Acute myocardial infarction
- Extravasation injury from anthracycline injection
- Hypercupremia
- Left ventricular failure
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Daunorubic, cytarab (liposome)
No established safety and efficacy.
- 1 Day – 18 Years
- No established safety and efficacy.
Daunorubicin
- Severity Level:
D
- Additional Notes:
Contraindicated
Cytarabine (liposomal)
Breastfeeding not recommended due to potential risk to infant
Insufficient human data; potential for severe toxicity
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Breastfeeding not recommended due to potential risk to infant |
Daunorubicin
Breastfeeding not recommended due to potential risk to infant
Insufficient human data; potential for severe toxicity
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insufficient human data; potential for severe toxicity |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Daunorubicin-cytarabine Liposome
Hematologic: Geriatrics are at increased risk for prolonged and severe thrombocytopenia leading to hemorrhage. Monitor drug induced neutropenia. Cardiovascular: Concomitant use of cardiotoxic agents may increase the risk of cardiotoxicity. Assess cardiac function more frequently when coadministered with cardiotoxic agents.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication is not given the same way as similar products including daunorubicin, daunorubicin liposome, cytarabine, or cytarabine liposome. Do not use any of these similar products while using daunorubicin/cytarabine liposome injection. This medication may rarely cause serious (rarely fatal) heart problems (including heart failure).<br /><br />This effect may occur during treatment or months to years after treatment is completed. The risk of heart problems is increased if you have heart disease, or have had radiation treatment to the chest area, or use/have used drugs that can also cause heart problems. Tell your doctor right away if you notice symptoms such as irregular heartbeat, shortness of breath, swelling ankles/feet, unusual tiredness, or unusual/sudden weight gain.<br /><br /> This medication decreases bone marrow function, an effect that may lead to a low number of blood cells such as red cells, white cells, and platelets. This effect can cause anemia, decrease your body's ability to fight an infection, or cause easy bruising/bleeding. Tell your doctor right away if you develop any of the following symptoms: unusual tiredness, pale skin, signs of infection (such as sore throat that doesn't go away, fever, chills), easy bruising/bleeding.<br /><br /> This medication must be given only by injection into a vein. It must not be given by injection into a muscle or under the skin. If this medication accidentally leaks into the skin/muscle around the injection site, it may cause severe damage. Tell your doctor right away if you notice redness, pain, or swelling at or near the injection site.
| Acute myeloid leukemia | |
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
| 0-9 | A-Z |
|---|---|
| C92.0 | Acute myeloblastic leukemia |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.4 | Acute promyelocytic leukemia |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.5 | Acute myelomonocytic leukemia |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
| C92.6 | Acute myeloid leukemia with 11q23-abnormality |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C93.0 | Acute monoblastic/monocytic leukemia |
| C93.00 | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.02 | Acute monoblastic/monocytic leukemia, in relapse |
| C94.4 | Acute panmyelosis with myelofibrosis |
| C94.40 | Acute panmyelosis with myelofibrosis not having achieved remission |
| C94.42 | Acute panmyelosis with myelofibrosis, in relapse |
Formulary Reference Tool